This trial has been completed.

Condition low grade gliomas
Treatment proton radiation therapy
Sponsor Massachusetts General Hospital
Collaborator National Cancer Institute (NCI)
Start date July 2007
End date August 2015
Trial size 20 participants
Trial identifier NCT00681473, 06-195


In this research study, we are looking to study the side effects from the use of proton radiation in treating people with low-grade gliomas that are recommended radiation treatment. We expect response of the tumors to be the same with proton radiation as compared to standard 3D conformal radiation therapy, but also expect less side effects from radiation.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Proton radiation therapy daily (Monday through Friday) for six weeks. This is a single arm study.
proton radiation therapy
Once daily, Monday through Friday, for 6 weeks.

Primary Outcomes

Number of Participants With Late Effects > 3 Months Post RT
time frame: 5 years

Secondary Outcomes

Percentage of Participants With Progression Free Survival
time frame: At 1, 3, and 5 years
Percentage of Participants With Overall Survival
time frame: At 1, 3, and 5 years

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Histologically confirmed low-grade gliomas, WHO classification II/IV or equivalent low grade histology, including protoplasmic, fibrillary, gemistocytic astrocytomas, and mixed variants such as oligoastrocytomas - Must have at least one of: (1) progressive or recurrent disease as defined by imaging, (2) persistence or progression of debilitating neurological symptoms, or (3) at risk of early progression as defined by either (a) age of 40 or older or (b) MIB-1 of 3% or greater - KPS of 70 or greater - 18 years of age or older - Surgical and medical/chemotherapeutic interventions are per physician's discretion and are acceptable - Must be able to speak and comprehend English Exclusion Criteria: - Other baseline neurocognitive or emotional disorders or deficits, including but not limited to head injury, CVA, TIA, or other cerebral insults with residual neuropsychiatric deficits, psychiatric disorders, learning disabilities, HIV positivity or other medical conditions at high risk of causing neurocognitive decline or emotional instability - Prior history of cranial irradiation - Pregnancy at the time of radiation treatment - Unable to undergo MRI scans (e.g., embedded ferromagnetic metal or pacemakers) - Comorbid illness or reason to suggest a life expectancy of less than 5 years

Additional Information

Official title Late Effects of Proton Radiation Therapy in Patients With Low-Grade Glioma
Principal investigator Helen A. Shih, MD, MS, MPH
Description - Participants will receive radiation therapy for 6 weeks, given in daily doses, Monday through Friday, for a total of 30 treatments. - A medical history and physical examination will be performed prior to the start of radiation treatment, weekly during the 6 weeks of radiation and after the finish of radiation performed at 3 and 6 months and then annually for 5 years. - Hormonal function tests will be taken prior to the start of radiation treatment and after the finish of radiation treatment at 3 and 6 months, and annually for five years to assess the participants hormonal functions as they relate to the pituitary gland's function. - A brain MRI will be performed prior to the start of radiation treatment and then performed at 3 and 6 months after radiation treatment then annually for 5 years. - A neurocognitive exam will be performed prior to the start of radiation therapy, a limited exam 6 months after the completion of radiation therapy, and a complete exam annually for 5 years. - Quality of Life and Emotional Well-Being Questionnaires will be done before radiation begins, 2 months after radiation treatment, 6 months after radiation treatment and then annually for 5 years.
Trial information was received from ClinicalTrials.gov and was last updated in January 2017.
Information provided to ClinicalTrials.gov by Massachusetts General Hospital.